{"transactions":[{"id":1490197,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-05T23:23:19.000Z","date":"2024-06-03","kind":"sale","planned":false,"acquired":false,"shares":691525,"price":54.75,"value":37860993.75,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any."}],"balance_after":3340018,"source":{"system":"sec-edgar","filing":"0001415889-24-015676","document":"form4-06052024_110615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924015676/form4-06052024_110615.xml","form_type":"4"}},{"id":1490196,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-05T23:23:19.000Z","date":"2024-06-03","kind":"sale","planned":false,"acquired":false,"shares":131196,"price":54.75,"value":7182981.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any."}],"balance_after":633673,"source":{"system":"sec-edgar","filing":"0001415889-24-015676","document":"form4-06052024_110615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924015676/form4-06052024_110615.xml","form_type":"4"}},{"id":1693012,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-03T21:52:11.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":157000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":157000,"derivative":{"exercise_price":11.02,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":157000},"source":{"system":"sec-edgar","filing":"0001209191-24-000435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120919124000435/doc4.xml","form_type":"4"}},{"id":1740917,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-15T21:48:17.000Z","date":"2023-11-13","kind":"purchase","planned":false,"acquired":true,"shares":849854,"price":5.87,"value":4988642.98,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by Avalon BioVentures I, LP (ABV I). Avalon BioVentures GP LLC (ABV GP) is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any."}],"balance_after":849854,"source":{"system":"sec-edgar","filing":"0001209191-23-055352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120919123055352/doc4.xml","form_type":"4"}},{"id":2063010,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T21:34:51.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":110000,"derivative":{"exercise_price":14.02,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-23-001882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120919123001882/doc4.xml","form_type":"4"}},{"id":2444383,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T22:27:24.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":116750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on January 1, 2023 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":116750,"derivative":{"exercise_price":20.24,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":116750},"source":{"system":"sec-edgar","filing":"0001209191-22-001830","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120919122001830/doc4.xml","form_type":"4"}},{"id":2666560,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-06-16T22:11:02.000Z","date":"2021-06-15","kind":"exercise","acquired":false,"shares":900264,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion.  The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is Chief Financial Officer of Avalon Ventures and shares voting and investment power with respect to the shares held by ABV SPV. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.\nif any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1153238},"source":{"system":"sec-edgar","filing":"0001209191-21-041041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120919121041041/doc4.xml","form_type":"4"}},{"id":2666559,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-06-16T22:11:02.000Z","date":"2021-06-15","kind":"exercise","acquired":false,"shares":2105264,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion.  The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is Chief Financial Officer of Avalon Ventures and shares voting and investment power with respect to the shares held by ABV SPV. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.\nif any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2696843},"source":{"system":"sec-edgar","filing":"0001209191-21-041041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120919121041041/doc4.xml","form_type":"4"}},{"id":2666558,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-16T22:11:02.000Z","date":"2021-06-15","kind":"purchase","acquired":true,"shares":629411,"price":17,"value":10699987.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is Chief Financial Officer of Avalon Ventures and shares voting and investment power with respect to the shares held by ABV SPV. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.\nif any."}],"balance_after":4479492,"source":{"system":"sec-edgar","filing":"0001209191-21-041041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120919121041041/doc4.xml","form_type":"4"}},{"id":2666557,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-16T22:11:02.000Z","date":"2021-06-15","kind":"exercise","acquired":true,"shares":1153238,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is Chief Financial Officer of Avalon Ventures and shares voting and investment power with respect to the shares held by ABV SPV. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.\nif any."}],"balance_after":3850081,"source":{"system":"sec-edgar","filing":"0001209191-21-041041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120919121041041/doc4.xml","form_type":"4"}},{"id":2666556,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-16T22:11:02.000Z","date":"2021-06-15","kind":"exercise","acquired":true,"shares":2696843,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is Chief Financial Officer of Avalon Ventures and shares voting and investment power with respect to the shares held by ABV SPV. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.\nif any."}],"balance_after":2696843,"source":{"system":"sec-edgar","filing":"0001209191-21-041041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120919121041041/doc4.xml","form_type":"4"}},{"id":3303124,"issuer":{"id":152202,"kind":"organization","name":"Synthorx, Inc.","symbol":"THOR"},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-01-24T18:36:25.000Z","date":"2020-01-23","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":57,"value":1710000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, which provided for vesting of 100% of the shares subject to the option upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,710,000.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68)."}],"balance_after":0,"derivative":{"exercise_price":11,"expiration_date":"2028-12-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-004927","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1760431/000120919120004927/doc4.xml","form_type":"4"}},{"id":3303123,"issuer":{"id":152202,"kind":"organization","name":"Synthorx, Inc.","symbol":"THOR"},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-01-24T18:36:25.000Z","date":"2020-01-23","kind":"disposition_to_issuer","acquired":false,"shares":18723,"price":63.36,"value":1186289.28,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, which was immediately exercisable, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,186,289.28, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68)."}],"balance_after":0,"derivative":{"exercise_price":4.64,"expiration_date":"2028-08-29","underlying":"Common Stock","underlying_shares":18723},"source":{"system":"sec-edgar","filing":"0001209191-20-004927","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1760431/000120919120004927/doc4.xml","form_type":"4"}},{"id":3303122,"issuer":{"id":152202,"kind":"organization","name":"Synthorx, Inc.","symbol":"THOR"},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-01-24T18:36:25.000Z","date":"2020-01-23","kind":"other","acquired":false,"shares":1682086,"price":68,"value":114381848.0,"ownership":{"direct":false,"nature":"By Avalon X SPV I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is Chief Financial Officer and Partner of Avalon X SPV GP LLC, general partner of Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-004927","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1760431/000120919120004927/doc4.xml","form_type":"4"}},{"id":3303121,"issuer":{"id":152202,"kind":"organization","name":"Synthorx, Inc.","symbol":"THOR"},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-01-24T18:36:25.000Z","date":"2020-01-23","kind":"other","acquired":false,"shares":43688,"price":68,"value":2970784.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-004927","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760431/000120919120004927/doc4.xml","form_type":"4"}},{"id":3732469,"issuer":{"id":152202,"kind":"organization","name":"Synthorx, Inc.","symbol":"THOR"},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Series C Preferred Stock","published_at":"2018-12-13T18:36:39.000Z","date":"2018-12-11","kind":"exercise","acquired":false,"shares":1821156,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Avalon X SPV I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1.60224-to-1 basis. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1.60224-to-1 basis. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1.60224-to-1 basis. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is Chief Financial Officer and Partner of Avalon X SPV GP LLC, general partner of Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1136631},"source":{"system":"sec-edgar","filing":"0001209191-18-062518","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1760431/000120919118062518/doc4.xml","form_type":"4"}},{"id":3732468,"issuer":{"id":152202,"kind":"organization","name":"Synthorx, Inc.","symbol":"THOR"},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-13T18:36:39.000Z","date":"2018-12-11","kind":"purchase","acquired":true,"shares":545455,"price":11,"value":6000005.0,"ownership":{"direct":false,"nature":"By Avalon X SPV I, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were purchased at the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is Chief Financial Officer and Partner of Avalon X SPV GP LLC, general partner of Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any."}],"balance_after":1682086,"source":{"system":"sec-edgar","filing":"0001209191-18-062518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1760431/000120919118062518/doc4.xml","form_type":"4"}},{"id":3732467,"issuer":{"id":152202,"kind":"organization","name":"Synthorx, Inc.","symbol":"THOR"},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-13T18:36:39.000Z","date":"2018-12-11","kind":"exercise","acquired":true,"shares":1136631,"ownership":{"direct":false,"nature":"By Avalon X SPV I, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1.60224-to-1 basis. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1.60224-to-1 basis. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is Chief Financial Officer and Partner of Avalon X SPV GP LLC, general partner of Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any."}],"balance_after":1136631,"source":{"system":"sec-edgar","filing":"0001209191-18-062518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760431/000120919118062518/doc4.xml","form_type":"4"}},{"id":3739610,"issuer":{"id":152202,"kind":"organization","name":"Synthorx, Inc.","symbol":"THOR"},"owners":[{"id":90244,"kind":"person","name":"Reardon Tighe","position":1,"cik":"0001760431","reported_name":"Reardon Tighe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-12-07T17:37:01.000Z","date":"2018-12-06","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world."}],"balance_after":30000,"derivative":{"exercise_price":11,"expiration_date":"2028-12-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-18-061570","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760431/000120919118061570/doc4.xml","form_type":"4"}}]}